Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Novel Werner helicase inhibitors in MSI-high and MMR-deficient tumors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of Werner helicase inhibitors in patients with tumors exhibiting MSI high or MMR deficiency, highlighting their tolerability and efficacy with promising disease control rates and overall response rates. Ongoing trials are exploring combinations of Werner helicase inhibitors with immunotherapy agents, such as pembrolizumab, or standard of care agents, like bevacizumab. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I also discussed the example of a different class of agents called Werner helicase inhibitors, this time in patients with tumors with either MSI high or deficiency in MMR. And what we have seen is that these Werner helicase inhibitors are generally well-tolerated, mainly with GI toxicities. And they have led to patient benefit with a high disease control rate of approximately 70% and an overall response rate of about 15%...

I also discussed the example of a different class of agents called Werner helicase inhibitors, this time in patients with tumors with either MSI high or deficiency in MMR. And what we have seen is that these Werner helicase inhibitors are generally well-tolerated, mainly with GI toxicities. And they have led to patient benefit with a high disease control rate of approximately 70% and an overall response rate of about 15%. So there are different trials that are currently ongoing, mainly in combinations, either, for example, with immunotherapy agents such as pembrolizumab or with standard of care agents such as bevacizumab.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.